Progenics Pharmaceuticals Inc. (PGNX) Stock Quote

Detailed Quote for Progenics Pharmaceuticals Inc. (PGNX)

After Hours: $ 9.51

0.00 (0.00%)

Volume: 100

4:58 PM EST Feb 10, 2012

close 52 Week Information

52 Week High

February 3, 2012

Close: 10.4988

52 Week Low

August 8, 2011

Close: 4.50

Today

Last Price
9.51

Change $
0.48

Change %
4.80%

Tick
N/A

Bid
N/A

Bid Size
0

Ask
N/A

Ask Size
0

Open
9.82

High
9.845

Low
9.31

Prev Close
9.99

Last Trade
2/10/12

Volume
107.5 k

52 Wk Hi
10.4988

52 Wk Low
4.50

Market Cap
321.08 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
33,762,677

EPS (TTM)
0.04

PE Ratio
237.80

close Exchange Information Listed On Nasdaq Global Select (NGS) Exchange
NGS

News and Media for Progenics Pharmaceuticals Inc. (PGNX)

Sector News | Topic News

News for PGNX

Tue, Dec 20, 2011

7:00 AM

Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation - Business Wire

Wed, Nov 09, 2011

7:30 AM

Progenics Pharmaceuticals Announces Third Quarter 2011 Financial Results - Globe Newswire

Tue, Nov 08, 2011

1:34 PM

Progenics Pharmaceuticals to Participate in Investor Conferences - Globe Newswire

Thu, Nov 03, 2011

3:04 PM

Progenics to Host Conference Call to Review Third Quarter 2011 Financial Results on November 9 - Globe Newswire

Fri, Oct 14, 2011

3:18 PM

Progenics Pharmaceuticals to Present at NewsMakers Conference - Globe Newswire

Tue, Sep 20, 2011

1:20 PM

Cannabis Science Appoints New Investor Relations Manager - Marketwire

Fri, Sep 16, 2011

1:47 PM

Progenics Pharmaceuticals to Present at UBS Global Life Sciences Conference - Globe Newswire

Thu, Sep 15, 2011

7:30 AM

Progenics Pharmaceuticals Announces Strategic Focus on Oncology - Globe Newswire

Tue, Jun 28, 2011

8:00 AM

Progenics Submits RELISTOR(R) Supplemental NDA for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-Cancer Pain - Globe Newswire

Thu, Jun 02, 2011

8:01 AM

Progenics Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference - Globe Newswire

Fri, May 20, 2011

8:00 AM

Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients - Globe Newswire

Tue, May 10, 2011

8:01 AM

Progenics Pharmaceuticals Announces First Quarter 2011 Financial Results - Globe Newswire

Mon, May 09, 2011

4:46 PM

Progenics to Host First Quarter 2011 Financial Results Conference Call and Webcast May 10 - Globe Newswire

Wed, May 28, 2008

5:26 PM

New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study - Canada Newswire

5:16 PM

New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study - Canada Newswire

More News for PGNX >>

Tags for Progenics Pharmaceuticals Inc.

Research stocks or mutual funds related to Progenics Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to PGNX. The keywords below have been associated to PGNX by either user submission or electronic means.

biotechnology company aventis pharmaceuticals clinical trial logistics pharmaceuticals research pharmaceuticals international research merck schering plough pharmaceuticals chronic pain relief clinical trials data pharmaceutical market clinical trial research stock market shares pharmaceuticals companies chronic pain treatment generic pharmaceutical pharmaceuticals logistics niche pharmaceutical pharmaceutical study foot pain symptoms pharmaceuticals careers chronic pain job in pharmaceuticals mgi pharma opening pharmaceutical research and development financial statements annual report constipation pain intestinal pain rabies vaccine dupont pharmaceuticals pharmaceutical industry marketing stock market investment pharma manufacturing elisa antibody pharmaceuticals jobs pharma license rfp pharmaceuticals novartis pharmaceuticals pharmaceuticals supply chain pharmaceuticals hiring clinical research new york stock market elan pharmaceuticals chronic pain syndromes stock market day trading pharmaceuticals position pharmaceutical cro canadian stock market pharma companies rabies